Narcolepsy Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy), By Product (Central Nervous System Stimulants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Narcolepsy Therapeutics Market Size

The global narcolepsy therapeutics market size was valued at USD 4.94 billion in 2025 and is projected to grow from USD 5.35 billion in 2026 to USD 10.04 billion by 2034, registering a CAGR of 8.2% during the forecast period from 2026 to 2034. North America dominated the narcolepsy therapeutics market with a market share of 42.8% in 2025.

Narcolepsy is a chronic neurological disorder in which the brain's ability to regulate sleep-wake cycles is impaired. It can cause people to fall asleep during the day without warning. Narcolepsy therapeutics are medications and other interventions used to treat the symptoms of narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness, sudden loss of muscle tone (Cataplexy), hallucinations, sleep paralysis, and disrupted nighttime sleep. The primary goal of narcolepsy treatment is to improve daytime wakefulness and manage other symptoms to improve the overall quality of life for people who have the condition.

Increased research and development activities on narcolepsy treatments are likely to boost the narcolepsy therapeutics market share. Pharmaceutical companies and academic organizations are working hard to create new treatments for narcolepsy. R&D activities have picked up steam in recent years, resulting in the launch of novel treatment alternatives in the coming years. With ongoing research, technological advancements, and a focus on improving patient outcomes, the global market is expected to continue evolving. The future landscape of narcolepsy treatment is likely to be shaped by the development of novel therapies, increased awareness, and efforts to address diagnostic challenges.

Segmentation Analysis

By Treatment

The market is further segmented by treatment into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy. Narcolepsy with Cataplexy holds a significant market share. Narcolepsy with Cataplexy was identified as the largest revenue segment in 2022, with a market share of 55%. Narcolepsy with Cataplexy is a type of narcolepsy that is characterized by sudden episodes of muscle weakness or paralysis caused by strong emotions such as laughter or excitement. The treatment for this subtype frequently focuses on managing both excessive daytime sleepiness and cataplexy symptoms. Harmony Biosciences Holdings, Inc. received FDA approval for its WAKIX (pitolisant) in October 2020 to treat adult cataplexy associated with narcolepsy.

Furthermore, in some cases, Cataplexy is the confirming symptom for a conclusive diagnosis. Although Cataplexy is rarely the first symptom of narcolepsy, it affects approximately 75% of narcoleptic patients.

Excessive daytime sleepiness without Cataplexy is characterized by narcolepsy without Cataplexy. The primary goal of treatment for this subtype is to improve wakefulness and daily functioning by managing daytime sleepiness. The high prevalence of the disease and the increase in public awareness through awareness campaigns conducted by various networks, such as the U.S. Narcolepsy Network and the Europe Narcolepsy Network, are the key factors responsible for the growth of this segment.

Request Customizationto receive a tailored report.

By Product

The market can be further bifurcated by-products into CNS Stimulants, Sodium Oxybate, SSRI, and Tricyclic Antidepressants. Sodium Oxybate generates the most revenue in the market.With a revenue share of 50% in 2022, sodium oxybate dominated the global market and is expected to grow at the fastest CAGR during the forecast period. Sodium oxybate is a medication used to treat narcolepsy, specifically to manage Cataplexy and improve nighttime sleep. It is a CNS depressant that works on the brain to promote deep and restorative sleep. Sodium oxybate, when taken orally at bedtime and throughout the night, aids in regulating sleep patterns and reducing cataplexy episodes. It is an important therapeutic option for treating narcolepsy's excessive daytime sleepiness and cataplexy symptoms.

CNS stimulants are medications that act on the brain and spinal cord to increase alertness and arousal. CNS stimulants such as modafinil and armodafinil are commonly prescribed in narcolepsy treatment to alleviate excessive daytime sleepiness. These medications improve wakefulness by influencing neurotransmitters in the brain, improving focus, and decreasing sleepiness in people with narcolepsy.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America: Dominant Region with A Cagr of 8.4%

North America is the most significant global narcolepsy therapeutics market shareholder and is estimated to grow at a CAGR of 8.4% over the forecast period. The segment is growing due to increased R&D activities and result-oriented collaborations in research, academic, and corporate sectors. The market is expected to be driven by the availability of many products, increased R&D activities, and government-friendly initiatives; for example, according to a study published in September 2021 by Stanford Medicine, the extended-release of sodium oxybate reduced muscle weakness attacks in patients. Narcolepsy affects between 135,000 and 200,000 people in the United States, according to a fact sheet updated in November 2021 by the National Institute of Neurological Disorders and Stroke. However, the number could be much higher because this condition is frequently misdiagnosed. Given the high prevalence of narcolepsy in developed countries such as the United States, increased adoption of narcolepsy therapeutics will drive market growth in this region.

Furthermore, Stanford researchers demonstrated that once-nightly narcolepsy treatment is safe and effective in a phase 3 study, showing that an extended-release sodium oxybate reduces daytime sleepiness and attacks muscle weakness in narcolepsy patients. The increasing efficacy of narcolepsy treatments in the United States will result in increased adoption of these therapies, driving the growth of this market in this region. Furthermore, Wake Up Narcolepsy, a charity group, received USD 1 million in donations for neurological research illnesses such as narcolepsy in December 2021. The increase in donations for the development of narcolepsy treatments in the United States is expected to fuel the future growth of this market in this region.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific: Growing Region with A Cagr of 8.1%

Asia-Pacific is anticipated to exhibit a CAGR of 8.1% over the forecast period, with the region's rapid economic development, rising awareness among people, high disposable income, growing investments in pharmaceutical and biotechnology sectors, and supportive government initiatives. Furthermore, the thriving generics industry and improving healthcare facilities will drive further market growth in the coming years. The country's generative efforts to raise public awareness about sleep disorders, including narcolepsy, have made it a lucrative segment for the growth of the narcolepsy treatment market, given the emergence of local pharmaceutical players in China.

In addition, the annual incidence of narcolepsy in China is 0.79 per 100 people. Most patients visit multiple hospitals before diagnosis, with adults spending an average of 2.98 years and children and adolescents spending 0.7 years. However, a 2022 psychiatrist believes that the prevalence of narcolepsy in India may be lower than in the Western world. However, there are only a few published case reports of narcolepsy from the Indian subcontinent. As a result of the low prevalence of narcolepsy, the region's growth will be slower.

Europe holds a significant market share. According to Narcolepsy Therapeutics Market insights, Germany's market value share in the European narcolepsy treatment market increased by nearly 25%. The expansion is linked to the framework associated with new guidelines framed by the combined efforts of the European Sleep Research Society (ESRS), European Academy of Neurology (EAN), and European Narcolepsy Network (EU-NN) for the treatment of narcolepsy and associated sleep disorders in adults and children in the region.

Previously, the prevalence of narcolepsy in Europe was estimated to be 47 patients per 100,000 people, with a yearly incidence of 0.64-1.37 per 100,000. However, according to the European Narcolepsy Network (EU-NN) database, narcolepsy with Cataplexy is a rare disease, with a 0.02% prevalence in European populations. As a result, the need for treatment is also reduced. Furthermore, favorable reimbursement policies for therapeutic products, a robust clinical pipeline, and rising stress levels are expected to drive revenue growth.

List of Key and Emerging Players in Narcolepsy Therapeutics Market